Evaluating the differences among dermatologists’ approaches to abnormal laboratory results of patients using oral isotretinoin treatment for acne

IF 0.1 Q4 DERMATOLOGY
S. Sarıkaya Solak, Hande Yelgen, İmran Boğa
{"title":"Evaluating the differences among dermatologists’ approaches to abnormal laboratory results of patients using oral isotretinoin treatment for acne","authors":"S. Sarıkaya Solak, Hande Yelgen, İmran Boğa","doi":"10.4103/tjd.tjd_58_22","DOIUrl":null,"url":null,"abstract":"Background: Oral isotretinoin is one of the most frequently used treatment options in moderate and severe acne. Abnormal laboratory results may occur during the treatment and there may be differences in approach to these abnormal laboratory results among dermatologists. Aim: In this study, we aimed to retrospectively evaluate the differences in approach to abnormal laboratory results and treatment modifications of dermatologists during oral isotretinoin treatment. Materials and Methods: Data of 207 patients who had oral isotretinoin treatment for acne between January 2013 and October 2020 were included in this study. Baseline and follow-up laboratory results were reviewed. All treatment modifications were noted and evaluated with relevant literature. Results: Among 207 patients, 28 (13.5%) had treatment modifications due to the abnormal laboratory results, and all of them were due to elevation of lipid and liver enzyme levels. The dose was reduced in 24 (11.6%) patients and the treatment was discontinued in 4 (1.9%) patients. Treatment modification was not compulsory in the vast majority of patients (26 of 28) according to the relevant literature. Conclusion: The results of the present study showed that unnecessary treatment modifications due to the abnormal laboratory results can be made by dermatologists during oral isotretinoin treatment for acne. Educational programs for dermatologists and more detailed guidelines may prevent these unnecessary treatment modifications.","PeriodicalId":42454,"journal":{"name":"Turk Dermatoloji Dergisi-Turkish Journal of Dermatology","volume":"55 1","pages":"16 - 18"},"PeriodicalIF":0.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turk Dermatoloji Dergisi-Turkish Journal of Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/tjd.tjd_58_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Oral isotretinoin is one of the most frequently used treatment options in moderate and severe acne. Abnormal laboratory results may occur during the treatment and there may be differences in approach to these abnormal laboratory results among dermatologists. Aim: In this study, we aimed to retrospectively evaluate the differences in approach to abnormal laboratory results and treatment modifications of dermatologists during oral isotretinoin treatment. Materials and Methods: Data of 207 patients who had oral isotretinoin treatment for acne between January 2013 and October 2020 were included in this study. Baseline and follow-up laboratory results were reviewed. All treatment modifications were noted and evaluated with relevant literature. Results: Among 207 patients, 28 (13.5%) had treatment modifications due to the abnormal laboratory results, and all of them were due to elevation of lipid and liver enzyme levels. The dose was reduced in 24 (11.6%) patients and the treatment was discontinued in 4 (1.9%) patients. Treatment modification was not compulsory in the vast majority of patients (26 of 28) according to the relevant literature. Conclusion: The results of the present study showed that unnecessary treatment modifications due to the abnormal laboratory results can be made by dermatologists during oral isotretinoin treatment for acne. Educational programs for dermatologists and more detailed guidelines may prevent these unnecessary treatment modifications.
评估皮肤科医生对口服异维甲酸治疗痤疮患者异常实验室结果的处理方法的差异
背景:口服异维甲酸是中重度痤疮最常用的治疗方法之一。在治疗过程中可能会出现异常的实验室结果,皮肤科医生对这些异常实验室结果的处理方法可能存在差异。目的:在本研究中,我们旨在回顾性评估皮肤科医生在口服异维甲酸治疗期间对异常实验室结果的处理方法和治疗方法的差异。材料与方法:本研究纳入2013年1月至2020年10月期间口服异维甲酸治疗痤疮的207例患者的数据。回顾了基线和随访的实验室结果。所有的治疗修改都被记录下来,并通过相关文献进行评价。结果:207例患者中,28例(13.5%)因实验室检查结果异常而改变治疗方案,均为脂质和肝酶水平升高所致。24例(11.6%)患者减少剂量,4例(1.9%)患者停止治疗。根据相关文献,绝大多数患者(28例中的26例)的治疗改变不是强制性的。结论:本研究结果表明,皮肤科医生在口服异维甲酸治疗痤疮时,可因实验室结果异常而进行不必要的治疗修改。皮肤科医生的教育计划和更详细的指导方针可以防止这些不必要的治疗修改。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.50
自引率
0.00%
发文量
13
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信